Pharma Firm Dr Reddy's Acquires MenoLabs' Women Health Brands in US | India Pharma Outlook

Pharma Firm Dr Reddy's Acquires MenoLabs' Women Health Brands in US

India Pharma Outlook Team | Thursday, 04 January 2024

 India Pharma Outlook Team

Dr. Reddy's purchased Amyris' MenoLabs business, a prominent women's health and dietary supplement branded portfolio, for $3 million in a Chapter 11 bankruptcy action in the United States Bankruptcy Court for the District of Delaware.

Dr. Reddy’s acquired the entire MenoLabs supplements portfolio which includes seven branded products to treat perimenopause and menopause. Brands include MenoFit and MenoGlow probiotics, Happy Fiber and Well Rested dietary supplements, Athena’s Shield menopause support supplement, and Goodness Glow and Keep Glowing Gorgeous supplements for healthy aging support, as per economic times.

The transaction also includes the MenoLife health tracker app, which supports the product line and provides consumers with community, education, and information about menopause.

MenoLabs' product selection is available in the United States, largely through the brand's own website and various e-commerce marketplaces such as Amazon and Walmart.

“The MenoLabs acquisition will serve as a catalyst to accelerate growth in this space and build upon our aspiration to lead in the fast-growing women’s nutritional and wellness markets,” said Marc Kikuchi, CEO for Dr. Reddy’s in North America.

“The acquisition complements Dr. Reddy’s U.S. self-care and wellness business portfolio of brands .. we are well-positioned to successfully integrate and grow the business,” Kikuchi said.

Dr. Reddy's Laboratories is a worldwide pharmaceutical firm headquartered in Hyderabad, India. Kallam Anji Reddy, who had worked at the mentor institute Indian Drugs & Pharmaceuticals Limited, started the company.[2] Dr. Reddy makes and sells a wide range of medications in India and around the world. Over 190 pharmaceuticals are produced, as well as 60 active pharmaceutical ingredients (APIs) for drug manufacturing, diagnostic kits, critical care, and biotechnology.

© 2024 India Pharma Outlook. All Rights Reserved.